Get the Stockscreener App
34.46
3.14%
1.05
After Hours:
34.00
-0.46
-1.33%
Lyell Immunopharma Inc stock is traded at $34.46, with a volume of 64,901.
It is up +3.14% in the last 24 hours and up +95.46% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$33.41
Open:
$33.8
24h Volume:
64,901
Relative Volume:
1.33
Market Cap:
$732.07M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-43.62
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+36.48%
1M Performance:
+95.46%
6M Performance:
+253.80%
1Y Performance:
+126.65%
1-Day Range:
$32.75
$35.16
1-Week Range:
$25.50
$35.16
52-Week Range:
$7.65
$35.16
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
34.46 | 709.76M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
1,820,634 Shares in Lyell Immunopharma, Inc. $LYEL Bought by ARCH Venture Management LLC - Defense World
Lyell ImmunoPharma announces new data from trial of rondecabtagene autoleucel - MSN
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month HighShould You Buy? - MarketBeat
Aug Technicals: Why Lyell Immunopharma Inc stock could outperform in 2025Weekly Gains Summary & Smart Swing Trading Alerts - moha.gov.vn
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 11.4%Should You Buy? - MarketBeat
What analysts say about Lyell Immunopharma Inc stockConsumer Goods Stocks & High Return Capital Growth - earlytimes.in
Lyell Immunopharma Shares Rise After HC Wainwright Upgrade - marketscreener.com
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression - TradingView — Track All Markets
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - GlobeNewswire Inc.
LYEL Analyst Rating Upgrade: HC Wainwright & Co. Sets New Price Target | LYEL Stock News - GuruFocus
HC Wainwright & Co. Upgrades Lyell Immunopharma (LYEL) - Nasdaq
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
Lyell Immunopharma stock rises on strong cancer therapy trial data By Investing.com - Investing.com Nigeria
Lyell Immunopharma stock rises on strong cancer therapy trial data - Investing.com
Lyell Immunopharma Presents Promising CAR T-Cell Data - TipRanks
Lyell Immunopharma (Nasdaq: LYEL) posts 76% complete responses with ronde-cel in LBCL - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High – Here’s What Happened - Defense World
Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement - TipRanks
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 11.6%Should You Buy? - MarketBeat
Will Lyell Immunopharma Inc. stock sustain high P E ratiosTrade Signal Summary & Growth Oriented Trading Recommendations - Newser
Decheng Capital LLC Sells 11,313,875 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
ASH 2025 Roundup: Companies With Key Data Presentations - RTTNews
What drives Lyell Immunopharma Inc stock priceHigh Beta Stocks & Free High Yield Growth Strategies - earlytimes.in
Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week HighHere's What Happened - MarketBeat
Lyell Immunopharma Secures Global Rights for LYL273 - MSN
Published on: 2025-11-26 22:33:12 - BỘ NỘI VỤ
Foresite Capital Management V LLC Trims Stock Position in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Lyell Immunopharma (LYEL) Sees Price Target Doubling by HC Wainw - GuruFocus
ETFs Investing in Lyell Immunopharma, Inc. Stocks - TradingView
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy - simplywall.st
Is Lyell Immunopharma Inc. stock trading at a premium valuationJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
How Lyell Immunopharma Inc. stock performs in rate cut cyclesJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Will Lyell Immunopharma Inc. stock pay special dividendsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Real time social sentiment graph for Lyell Immunopharma Inc.Weekly Profit Report & Reliable Volume Spike Trade Alerts - newser.com
Will Lyell Immunopharma Inc. benefit from macro trendsQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
How Lyell Immunopharma Inc. stock performs in weak economyTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
Is it too late to sell Lyell Immunopharma Inc.Weekly Investment Recap & Daily Stock Momentum Reports - newser.com
Is Lyell Immunopharma Inc. stock attractive for retirement portfoliosLayoff News & Safe Entry Point Alerts - newser.com
Lyell Immunopharma Secures Global Rights to CAR T-Cell Candidate for Metastatic Colorectal Cancer - Global Legal Chronicle
Strategies to average down on Lyell Immunopharma Inc.July 2025 Institutional & Smart Investment Allocation Tips - newser.com
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):